Current location - Health Preservation Learning Network - Slimming men and women - Four therapeutic concepts of naokangning capsule
Four therapeutic concepts of naokangning capsule
Randomized, single-blind and controlled trials were used. Subjects who met the inclusion criteria were randomly divided into Naokangning capsule group and control group according to the random number table 1: 1. 60 cases met the criteria of case selection, including 30 cases in Naokangning capsule group and 30 cases in control group.

The diagnostic criteria of western medicine refer to the diagnostic criteria and differential diagnosis of Parkinson's disease and Parkinson's syndrome formulated by 1984 national seminar on extrapyramidal diseases, and the diagnostic criteria of traditional Chinese medicine refer to 19 1 the diagnostic and therapeutic evaluation criteria of traditional Chinese medicine for atrial fibrillation in the elderly (draft 4) formulated by the third academic seminar of the All-China Society of Traditional Chinese Medicine. The unified Parkinson's disease rating scale and the improved Hoehn Yahr five-stage grading standard were used to evaluate the condition, and the quality of life was evaluated with reference to the SF-36 health questionnaire. Syndrome differentiation of TCM belongs to wind-driven syndrome of liver and kidney yin deficiency. Both groups were treated with Naokangning capsule or placebo capsule on the basis of the original treatment, and observed for 3 months. UPDRS score in naokangning capsule group showed a downward trend. The number of patients with HY grade 1-3 in Naokangning capsule group increased from 28 to 29, the number of patients with grade 4 decreased from 2 to 1, the number of patients with HY grade 1-3 in control group decreased from 27 to 26, and the number of patients with grade 4 increased from 3 to 4.

In Naokangning capsule group, the daily dose of Madopar tablets decreased from 425.5±296.2mg to 375.5±225.6mg, which was 1 1.75% lower than that before treatment.

The total effective rate of syndrome in Naokangning capsule group was 93.67%, and that in control group was 50.0%, with significant difference (P 0.05).

The symptoms such as limb contracture, bradykinesia, stiff neck, dizziness, insomnia, dreaminess, night sweats, lumbago and leg pain, constipation and so on were obviously improved in the Naokangning capsule group (P 0.05).

The "off period" of Naokangning capsule group was shortened by 87% on average, while the "on period" was prolonged by 79% on average.

After taking the medicine, the scores of quality of life in all aspects were obviously improved, which was significantly different from that in the control group. Naokangning capsule may have neuroprotective effect on MPTP-induced PD, and its protective mechanism may involve: increasing GSH content in substantia nigra of PD mice, scavenging free radicals, reducing MDA and NOS content, and preventing oxidative stress induced by MPTP.